Trial Profile
A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Pembrolizumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 25 Jan 2020 Results of biomarker analysis for UPCI 14-118 has been presented at the 2020 Gastrointestinal Cancers Symposium
- 09 Sep 2019 Status changed from active, no longer recruiting to completed.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology